地舒单抗对2型糖尿病患者糖代谢及骨代谢影响的研究

Research on the effect of desumab on glucose metabolism and bone metabolism in patients with type 2 diabetes

2型糖尿病是由于胰岛素分泌不足和(或)胰岛素抵抗导致血糖升高的慢性疾病,在其诸多并发症中,骨质疏松症因其早期无明显症状,常常被人们忽视。新型抗骨质疏松药物RANKL抑制剂——地舒单抗是全人源化单克隆抗体(IgG2类),有抑制骨吸收,增加骨密度的作用,同时可能对糖代谢有一定改善作用。目前糖尿病性骨质疏松症临床上尚无理想解决方案。因此寻找一种既能改善骨代谢又能控制血糖的临床药物尤为重要。本文将系统综述地舒单抗对2型糖尿病糖代谢及骨代谢影响最新进展,为糖尿病性骨质疏松症合理应用地舒单抗提供理论基础。

Type 2 diabetes is a chronic disease with elevated blood sugar due to insufficient insulin secretion and(or)insulin resistance.Among its many complications,osteoporosis is often ignored because it has no obvious symptoms in its early stage.The novel anti osteoporosis drug RANKL inhibitor,Desumab,is a fully humanized monoclonal antibody(IgG2 class)that inhibits bone resorption,increases bone density,and may also have a certain improvement effect on glucose metabolism.At present,there is no ideal solution for diabetes osteoporosis clinically.Therefore,it is particularly important to find a clinical drug that can improve bone metabolism and control blood sugar.This article will systematically review the latest progress of the effects of desumab on glucose metabolism and bone metabolism in type 2 diabetes,and provide a theoretical basis for the rational use of desumab in diabetes induced osteoporosis.